Skip to main content

2024 Program

hands shaking

Loading

PTM Therapeutics, Inc.

October 16, 2024
Hunt Room
Oncology
PTM Therapeutics, Inc.
PTM Therapeutics was founded in 2020 based on the realization that post-translational modifications create highly specific disease targets for therapeutic antibodies. Our oncology program utilizes an antibody-drug conjugate (ADC) approach to treating metastatic colon cancer. We are targeting a glycan target that is upregulated on primary colon cancers and colon cancer metastases. We have xenograft data showing efficacy and safety. We also pursuing a second program for the treatment of colitis including radiation-induced colitis. We are currently raising a seed round to support crucial research to enable IND enabling activities.
Speakers
Jennifer Cheng - PhD, Co-founder & CEO - PTM Therapeutics, Inc.

DOUBLE HELIX SPONSOR

HELIX SPONSOR

PREMIER SPONSOR

CONFERENCE SPONSORS